liothyronine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1585 6893-02-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • liothyronine
  • liothyronine sodium
  • triiodothyronine
  • liothyronin
A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
  • Molecular weight: 650.98
  • Formula: C15H12I3NO4
  • CLOGP: 2.33
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 3
  • TPSA: 92.78
  • ALOGS: -4.52
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mcg O
60 mcg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 8, 1956 FDA KING PHARMS R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sensitisation 338.27 14.28 83 12364 2285 56277335
Polycystic ovaries 315.32 14.28 84 12363 3230 56276390
Ejection fraction 275.07 14.28 66 12381 1649 56277971
Hypothyroidism 262.26 14.28 140 12307 38056 56241564
Rhinitis allergic 241.40 14.28 85 12362 8389 56271231
Blood test abnormal 207.40 14.28 85 12362 12699 56266921
Carpal tunnel syndrome 194.26 14.28 90 12357 18054 56261566
Sleep apnoea syndrome 191.50 14.28 100 12347 25961 56253659
Sleep disorder due to a general medical condition 191.46 14.28 73 12374 9017 56270603
Burning sensation 147.55 14.28 106 12341 48590 56231030
Nephrectomy 135.81 14.28 35 12412 1178 56278442
Cardiac disorder 132.44 14.28 97 12350 45790 56233830
Fibromyalgia 116.14 14.28 100 12347 59503 56220117
Renal disorder 114.63 14.28 75 12372 29530 56250090
Gastrooesophageal reflux disease 103.60 14.28 109 12338 83148 56196472
Asthma 95.43 14.28 121 12326 112649 56166971
Ejection fraction abnormal 91.08 14.28 25 12422 1075 56278545
Loss of personal independence in daily activities 82.98 14.28 96 12351 81273 56198347
Therapeutic product effect incomplete 74.64 14.28 104 12343 105927 56173693
Headache 53.96 14.28 255 12192 558789 55720831
Hypertension 48.61 14.28 141 12306 244137 56035483
Hyperthyroidism 42.54 14.28 30 12417 13322 56266298
Urine chloride decreased 39.65 14.28 8 12439 86 56279534
Suicidal ideation 36.71 14.28 54 12393 57688 56221932
Wheezing 36.41 14.28 62 12385 74964 56204656
Urine sodium decreased 34.97 14.28 8 12439 161 56279459
Rheumatoid arthritis 33.13 14.28 22 12425 382582 55897038
Weight increased 31.60 14.28 117 12330 229586 56050034
Myopathy 31.15 14.28 22 12425 9790 56269830
Palpitations 30.74 14.28 68 12379 99604 56180016
Product substitution issue 27.39 14.28 24 12423 14575 56265045
Thyroid function test abnormal 24.69 14.28 13 12434 3420 56276200
Drug intolerance 24.60 14.28 14 12433 264804 56014816
Systemic lupus erythematosus 24.49 14.28 5 12442 180073 56099547
Glossodynia 23.49 14.28 3 12444 152455 56127165
Feeling abnormal 22.66 14.28 73 12374 133529 56146091
Arthropathy 22.65 14.28 8 12439 200267 56079353
Acute kidney injury 21.97 14.28 13 12434 240750 56038870
Blood thyroid stimulating hormone increased 21.49 14.28 15 12432 6548 56273072
Wound 20.75 14.28 3 12444 138801 56140819
Maternal exposure during pregnancy 20.71 14.28 8 12439 189545 56090075
Tri-iodothyronine increased 20.35 14.28 5 12442 138 56279482
Blood thyroid stimulating hormone abnormal 18.72 14.28 7 12440 817 56278803
Nail growth abnormal 18.02 14.28 6 12441 499 56279121
Thyroid cancer 17.48 14.28 12 12435 5104 56274516
Peak expiratory flow rate decreased 16.87 14.28 6 12441 608 56279012
Blood thyroid stimulating hormone decreased 16.81 14.28 11 12436 4322 56275298
Product quality issue 16.42 14.28 27 12420 31709 56247911
Thrombocytopenia 16.17 14.28 5 12442 136219 56143401
Death 16.10 14.28 32 12415 341394 55938226
Reaction to excipient 15.72 14.28 7 12440 1277 56278343
Pre-existing condition improved 15.59 14.28 13 12434 7385 56272235
Tri-iodothyronine decreased 15.45 14.28 4 12443 137 56279483
Product dose omission issue 15.17 14.28 87 12360 204666 56074954
Scar 14.94 14.28 16 12431 12417 56267203
Hospitalisation 14.58 14.28 43 12404 74957 56204663
General physical health deterioration 14.38 14.28 10 12437 170000 56109620

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Performance enhancing product use 50.50 23.37 8 1593 98 31695645
Rhythm idioventricular 48.95 23.37 9 1592 277 31695466
Secondary hypogonadism 48.73 23.37 9 1592 284 31695459
Thyrotoxic periodic paralysis 43.52 23.37 7 1594 95 31695648
Autoimmune thyroiditis 41.97 23.37 10 1591 1095 31694648
Loose associations 39.36 23.37 6 1595 56 31695687
Glucose tolerance decreased 37.91 23.37 6 1595 73 31695670
Diffuse vasculitis 37.61 23.37 6 1595 77 31695666
Sinus arrest 34.09 23.37 9 1592 1492 31694251
Feelings of worthlessness 30.37 23.37 6 1595 272 31695471
Haematocrit increased 27.51 23.37 8 1593 1889 31693854
Pressure of speech 27.23 23.37 6 1595 464 31695279
Hyperthyroidism 26.99 23.37 12 1589 9619 31686124
Insulin-like growth factor increased 26.41 23.37 7 1594 1178 31694565
Blood prolactin decreased 24.87 23.37 5 1596 248 31695495
Systolic hypertension 24.43 23.37 5 1596 271 31695472

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sensitisation 353.84 15.77 81 10840 2392 70915131
Polycystic ovaries 347.01 15.77 82 10839 2790 70914733
Ejection fraction 286.12 15.77 64 10857 1698 70915825
Rhinitis allergic 251.68 15.77 82 10839 9213 70908310
Hypothyroidism 230.70 15.77 121 10800 45634 70871889
Carpal tunnel syndrome 220.48 15.77 87 10834 16970 70900553
Blood test abnormal 211.92 15.77 81 10840 14509 70903014
Sleep disorder due to a general medical condition 195.76 15.77 70 10851 10406 70907117
Sleep apnoea syndrome 177.74 15.77 91 10830 32622 70884901
Fibromyalgia 160.72 15.77 97 10824 47777 70869746
Burning sensation 159.36 15.77 100 10821 52770 70864753
Nephrectomy 134.62 15.77 35 10886 1768 70915755
Cardiac disorder 134.47 15.77 94 10827 59321 70858202
Gastrooesophageal reflux disease 123.06 15.77 106 10815 90733 70826790
Renal disorder 109.76 15.77 70 10851 37939 70879584
Asthma 95.68 15.77 105 10816 120688 70796835
Loss of personal independence in daily activities 91.22 15.77 87 10834 84823 70832700
Ejection fraction abnormal 83.87 15.77 24 10897 1739 70915784
Therapeutic product effect incomplete 82.68 15.77 97 10824 119785 70797738
Hyperthyroidism 65.54 15.77 40 10881 20051 70897472
Headache 61.20 15.77 212 10709 580193 70337330
Hypertension 57.53 15.77 135 10786 295898 70621625
Urine chloride decreased 41.43 15.77 8 10913 100 70917423
Performance enhancing product use 40.39 15.77 8 10913 115 70917408
Wheezing 36.99 15.77 58 10863 94112 70823411
Secondary hypogonadism 36.87 15.77 9 10912 351 70917172
Thyrotoxic periodic paralysis 35.32 15.77 7 10914 101 70917422
Urine sodium decreased 33.66 15.77 8 10913 278 70917245
Rhythm idioventricular 33.45 15.77 9 10912 519 70917004
Loose associations 32.39 15.77 6 10915 59 70917464
Glucose tolerance decreased 31.00 15.77 6 10915 76 70917447
Tri-iodothyronine increased 29.98 15.77 7 10914 225 70917298
Insulin-like growth factor increased 29.95 15.77 11 10910 1760 70915763
Diffuse vasculitis 28.92 15.77 6 10915 110 70917413
Suicidal ideation 27.51 15.77 43 10878 69553 70847970
Blood thyroid stimulating hormone decreased 26.24 15.77 14 10907 5440 70912083
Myopathy 25.72 15.77 22 10899 18590 70898933
Weight increased 24.08 15.77 87 10834 242244 70675279
Thrombocytopenia 21.88 15.77 5 10916 239105 70678418
Autoimmune thyroiditis 21.75 15.77 11 10910 3831 70913692
Thyroid function test abnormal 21.23 15.77 10 10911 2987 70914536
Blood thyroid stimulating hormone increased 20.53 15.77 14 10907 8465 70909058
Feelings of worthlessness 20.20 15.77 6 10915 495 70917028
Palpitations 19.82 15.77 49 10872 110704 70806819
Feeling abnormal 19.46 15.77 57 10864 142262 70775261
Product dose omission issue 18.24 15.77 74 10847 217394 70700129
Product substitution issue 18.03 15.77 18 10903 18495 70899028
Sinus arrest 17.60 15.77 9 10912 3206 70914317
Immunoglobulins decreased 17.47 15.77 7 10914 1417 70916106
Product preparation error 17.39 15.77 10 10911 4492 70913031
Drug withdrawal syndrome 16.98 15.77 23 10898 32692 70884831
Acute kidney injury 16.45 15.77 30 10891 474594 70442929
Pyrexia 16.42 15.77 44 10877 606908 70310615
Nail growth abnormal 16.30 15.77 5 10916 460 70917063
Pressure of speech 15.93 15.77 6 10915 1029 70916494

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H03AA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
ATC H03AA03 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
FDA CS M0021977 Triiodothyronine
FDA EPC N0000175946 l-Triiodothyronine
CHEBI has role CHEBI:60311 thyroid hormones
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Goiter indication 3716002 DOID:12176
Myxedema coma indication 21263006
Hypothyroidism indication 40930008 DOID:1459
Myxedema indication 43153006 DOID:11634
Congenital hypothyroidism indication 190268003 DOID:0050328
Simple goiter indication 267369002
Malignant tumor of thyroid gland indication 363478007 DOID:1781
T3 Suppression for Thyroid Function Test indication
Mild Hypothyroidism indication
Diagnostic Test for Thyroid Dysfunction indication
Myocardial infarction contraindication 22298006 DOID:5844
Thyrotoxic crisis contraindication 29028009 DOID:12837
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Osteoporosis contraindication 64859006 DOID:11476
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Angina pectoris contraindication 194828000
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Disorder of coronary artery contraindication 414024009




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Hypothyroidism Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Cytobin Tablets Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.08 acidic
pKa2 8.12 acidic
pKa3 8.77 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Thyroid hormone receptor alpha Nuclear hormone receptor AGONIST Kd 10.24 CHEMBL CHEMBL
Thyroid hormone receptor beta Nuclear hormone receptor AGONIST Ki 10.10 CHEMBL CHEMBL
Adenosine receptor A1 GPCR Ki 6.62 DRUG MATRIX
Cytochrome P450 2C9 Enzyme EC50 6.30 WOMBAT-PK
Prothrombin Enzyme EC50 8.92 CHEMBL
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor Kd 6.15 CHEMBL
Proliferating cell nuclear antigen Nuclear other IC50 5.44 CHEMBL
THAP domain-containing protein 1 Unclassified EC50 9 WOMBAT-PK
GABA-A receptor; anion channel Ion channel IC50 4.64 CHEMBL
Thyroid hormone receptor beta Transcription factor IC50 8.74 CHEMBL
GABA-A receptor; anion channel Ion channel EC50 5.15 CHEMBL

External reference:

IDSource
4022167 VUID
N0000020173 NUI
D01011 KEGG_DRUG
55-06-1 SECONDARY_CAS_RN
4018002 VANDF
4022167 VANDF
C0041014 UMLSCUI
CHEBI:18258 CHEBI
T3 PDB_CHEM_ID
CHEMBL1544 ChEMBL_ID
CHEMBL1201119 ChEMBL_ID
D014284 MESH_DESCRIPTOR_UI
DB00279 DRUGBANK_ID
2634 IUPHAR_LIGAND_ID
653 INN_ID
06LU7C9H1V UNII
5920 PUBCHEM_CID
10814 RXNORM
1964 MMSL
4982 MMSL
d00658 MMSL
002133 NDDF
004882 NDDF
126204001 SNOMEDCT_US
350358003 SNOMEDCT_US
61275002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2178 TABLET 25 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2179 TABLET 5 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2180 TABLET 50 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 16590-303 TABLET 50 1 ORAL ANDA 13 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-166 TABLET 5 ug ORAL ANDA 24 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-167 TABLET 25 ug ORAL ANDA 24 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-168 TABLET 50 ug ORAL ANDA 24 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 33261-964 TABLET 5 ug ORAL ANDA 25 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 39822-0151 INJECTION, SOLUTION 10 ug INTRAVENOUS ANDA 25 sections
Triostat HUMAN PRESCRIPTION DRUG LABEL 1 42023-120 INJECTION 10 ug INTRAVENOUS NDA 25 sections
NP Thyroid 15 HUMAN PRESCRIPTION DRUG LABEL 2 42192-327 TABLET 2.25 ug ORAL unapproved drug other 23 sections
NP Thyroid 15 HUMAN PRESCRIPTION DRUG LABEL 2 42192-327 TABLET 2.25 ug ORAL unapproved drug other 23 sections
NP Thyroid 120 HUMAN PRESCRIPTION DRUG LABEL 2 42192-328 TABLET 18 ug ORAL unapproved drug other 22 sections
NP Thyroid 120 HUMAN PRESCRIPTION DRUG LABEL 2 42192-328 TABLET 18 ug ORAL unapproved drug other 22 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 42192-329 TABLET 4.50 ug ORAL unapproved drug other 22 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 42192-329 TABLET 4.50 ug ORAL unapproved drug other 22 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 42192-330 TABLET 9 ug ORAL unapproved drug other 22 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 42192-330 TABLET 9 ug ORAL unapproved drug other 22 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 42192-331 TABLET 13.50 ug ORAL unapproved drug other 22 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 42192-331 TABLET 13.50 ug ORAL unapproved drug other 22 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-417 TABLET 5 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-418 TABLET 25 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-419 TABLET 50 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-018 TABLET 5 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-019 TABLET 25 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-020 TABLET 50 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43063-884 TABLET 25 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43063-884 TABLET 25 ug ORAL ANDA 27 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 45865-566 TABLET 9 ug ORAL unapproved drug other 22 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-3131 TABLET 5 ug ORAL ANDA 27 sections